Loading clinical trials...
Loading clinical trials...
A Single-arm, Open-label, Multicenter Study Evaluating the Efficacy and Safety of GS1191-0445 Injection as a Single Dose in Chinese Subjects With Hemophilia A
Conditions
Interventions
GS1191-0445 injection
Locations
13
China
Anhui Provincial Hospital
Hefei, Anhui, China
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
First Hospital of Lanzhou University
Lanzhou, Gansu, China
Nanfang Hospital Southern Medical University
Guangzhou, Guangdong, China
North China University of Science and Technology Affiliated Hospital
Tangshan, Hebei, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Start Date
March 31, 2025
Primary Completion Date
November 30, 2026
Completion Date
November 30, 2030
Last Updated
December 9, 2025
NCT06820515
NCT07226206
NCT05987449
NCT04563520
NCT04645199
NCT05935358
Lead Sponsor
Gritgen Therapeutics Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions